IP Library Granted Patent US 11,844,763
Granted Patent B2
US 11,844,763 · App. 17/663,065 · Granted Dec 19, 2023

Pharmaceutical composition and method of manufacturing

Inventor: Gary J. Speier (Maple Grove,, MN)
A61K36/185A61K9/006A61K9/7023A61K31/352A61K36/00A61K2236/37
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,844,763
App. No.
17/663,065
Granted
Dec 19, 2023
Kind
B2
Abstract

The present invention provides for methods of obtaining an extract of Cannabis plant material as well as subsequent processing of the extract to provide a concentrate of Cannabis . The present invention also provides for pharmaceutical dosage forms (e.g., oral thin films and transdermal patches) that include the concentrate (or extract) of Cannabis , as well as methods of medical treatment that include administering the pharmaceutical dosage forms.

Claims (32)

1. A process for obtaining a first extract of Cannabis sativa, Cannabis indica, or combination thereof, enriched with at least one of: cannabinol; cannabinolic acid; Δ(9)-tetrahydrocannabinolic acid; Δ(9)-cannabidiol; Δ(9)-tetrahydrocannabidiolic acid; Δ(8)-tetrahydrocannabinolic acid; Δ(8)-tetrahydrocannabidiol; Δ(8)-tetrahydrocannabidiolic acid; Δ(9)-tetrahydrocannabivarin; cannabigerol; cannabigerolic acid; cannabichromene; cannabichromenic acid; cannabicyclol; and cannabicyclolic acid, and

a second extract of Cannabis sativa, Cannabis indica, or combination thereof, enriched with at least one of Δ(8)-tetrahydrocannabinol and Δ(9)-tetrahydrocannabinol, the process comprising:

(a) contacting Cannabis sativa, Cannabis indica, or a combination thereof, with carbon dioxide as the sole supercritical fluid solvent, at a pressure of 1,400 psi-3,800 psi, at a temperature of 35° C.-65° C., for a period of time of 1.5 hours to 8.5 hours, to provide an enriched extract of Cannabis sativa, Cannabis indica, or combination thereof; and

(b) removing the supercritical carbon dioxide from the extract; wherein the (a) contacting of the Cannabis sativa, Cannabis indica, or a combination thereof, with the supercritical carbon dioxide and then the (b) removing the supercritical carbon dioxide, is carried out two or more times, such that the process is a supercritical carbon dioxide fluid extraction;

wherein a first supercritical carbon dioxide fluid extraction is carried out such that:

(i) the contacting of the Cannabis sativa, Cannabis indica, or a combination thereof, with the supercritical carbon dioxide, is carried out at a pressure of 1,600 psi-2,000 psi, at a temperature of 35° C.-65° C., for a period of time of 1.5 hours-4.5 hours, to provide the first extract wherein a second supercritical carbon dioxide fluid extraction is carried out such that:

(ii) the contacting of the Cannabis sativa, Cannabis indica, or a combination thereof, with the supercritical carbon dioxide, is carried out at a pressure of 2,400 psi-3,600 psi, at a temperature of 35° C.-65° C., for a period of time of 3.5 hours-8.5 hours, to provide the second extract.

2. The process of claim 1 , wherein the first extract comprises no more than 5 wt. % in the aggregate Δ(8)-tetrahydrocannabinol and Δ(9)-tetrahydrocannabinol.

3. The process of claim 1 , wherein the first supercritical fluid extraction is carried out at a temperature of 44° C.-54° C.

4. The process of claim 1 , wherein the first supercritical fluid extraction is carried out for a period of time of 2 hours-4 hours.

5. The process of claim 1 , wherein the first extract is purified employing a technique selected from the group consisting of chromatography, adsorption, crystallization, distillation, liquid-liquid extraction, filtration, fractional distillation, precipitation, recrystallization, lyophilization, sublimation, and combinations thereof.

6. The process of claim 1 , wherein the first extract is purified employing a technique selected from the group consisting of chromatography, adsorption, crystallization, distillation, liquid-liquid extraction, filtration, fractional distillation, precipitation, recrystallization, lyophilization, sublimation, and combinations thereof, such that the first extract after the purification comprises at least 85 wt. % cannabinoids comprising at least one of cannabinolic acid; Δ(9)-tetrahydrocannabinolic acid; Δ(9)-cannabidiol; Δ(9)-tetrahydrocannabidiolic acid; Δ(8)-tetrahydrocannabinolic acid; Δ(8)-tetrahydrocannabidiol; Δ(8)-tetrahydrocannabidiolic acid; Δ(9)-tetrahydrocannabivarin; cannabigerol; cannabigerolic acid; cannabichromene; cannabichromenic acid; cannabicyclol; and cannabicyclolic acid.

7. The process of claim 1 , wherein the first extract is purified employing a technique selected from the group consisting of chromatography, adsorption, crystallization, distillation, liquid-liquid extraction, filtration, fractional distillation, precipitation, recrystallization, lyophilization, sublimation, and combinations thereof, such that the first extract after the purification comprises at least 98 wt. % cannabinoids comprising at least one of cannabinol; cannabinolic acid; Δ(9)-tetrahydrocannabinolic acid; Δ(9)-cannabidiol; Δ(9)-tetrahydrocannabidiolic acid; Δ(8)-tetrahydrocannabinolic acid; Δ(8)-tetrahydrocannabidiol; Δ(8)-tetrahydrocannabidiolic acid; Δ(9)-tetrahydrocannabivarin; cannabigerol; cannabigerolic acid; cannabichromene; cannabichromenic acid; cannabicyclol; and cannabicyclolic acid.

8. The process of claim 1 , wherein relative to the cannabis in step (a), the first extract includes a lower concentration of Δ(8)-tetrahydrocannabinol and Δ(9)-tetrahydrocannabinol.

9. The process of claim 1 , wherein the first extract comprises no more than 1 wt. % in the aggregate of Δ(8)-tetrahydrocannabinol and Δ(9)-tetrahydrocannabinol.

10. The process of claim 1 , wherein the second supercritical fluid extraction is carried out at a temperature of 44° C.-54° C.

11. The process of claim 1 , wherein the second supercritical fluid extraction is carried out for a period of time of 4-8 hours.

12. The process of claim 1 , wherein the second extract is purified employing a technique selected from the group consisting of chromatography, adsorption, crystallization, distillation, liquid-liquid extraction, filtration, fractional distillation, precipitation, recrystallization, lyophilization, sublimation, and combinations thereof.

13. The process of claim 2 , wherein the second extract is purified employing a technique selected from the group consisting of chromatography, adsorption, crystallization, distillation, liquid-liquid extraction, filtration, fractional distillation, precipitation, recrystallization, lyophilization, sublimation, and combinations thereof, such that the second extract enriched with Δ(8)-tetrahydrocannabinol and Δ(9)-tetrahydrocannabinol after the purification comprises at least 85 wt. % in the aggregate of Δ(8)-tetrahydrocannabinol and Δ(9)-tetrahydrocannabinol.

14. The process of claim 1 , wherein the second extract is purified employing a technique selected from the group consisting of chromatography, adsorption, crystallization, distillation, liquid-liquid extraction, filtration, fractional distillation, precipitation, recrystallization, lyophilization, sublimation, and combinations thereof, such that the second extract enriched with Δ(8)-tetrahydrocannabinol and Δ(9)-tetrahydrocannabinol after the purification comprises at least 95 wt. % in the aggregate of Δ(8)-tetrahydrocannabinol and Δ(9)-tetrahydrocannabinol.

15. The process of claim 1 , further comprising removing the supercritical fluid solvent from the second extract.

16. The process of claim 1 , wherein the second extract comprises at least about 65 wt. % in the aggregate of Δ(8)-tetrahydrocannabinol and Δ(9)-tetrahydrocannabinol.

17. The process of claim 1 , wherein relative to the cannabis in step (a), the second extract includes a lower concentration of cannabinoids comprising cannabinol; cannabinolic acid; Δ(9)-tetrahydrocannabinolic acid; Δ(9)-cannabidiol; Δ(9)-tetrahydrocannabidiolic acid; Δ(8)-tetrahydrocannabinolic acid; Δ(8)-tetrahydrocannabidiol; Δ(8)-tetrahydrocannabidiolic acid; Δ(9)-tetrahydrocannabivarin; cannabigerol; cannabigerolic acid; cannabichromene; cannabichromenic acid; cannabicyclol; cannabicyclolic acid; and combinations thereof.

18. The process of claim 1 , wherein relative to the cannabis in step (a), the second extract includes a lower concentration of cannabigerolic acid.

19. The process of claim 1 , wherein relative to the cannabis in step (a), the second extract includes a lower concentration of cannabinol.

20. The process of claim 1 , wherein relative to the cannabis in step (a), the second extract includes a lower concentration of Δ(9)-tetrahydrocannabinolic acid.

21. The process of claim 1 , wherein relative to the cannabis in step (a), the second extract includes a lower concentration of Δ(9)-cannabidiol.

22. The process of claim 1 , wherein relative to the cannabis in step (a), the second extract includes a lower concentration of Δ(9)-tetrahydrocannabidiolic acid.

23. The process of claim 1 , wherein the relative to the cannabis in step (a), the second extract includes a higher concentration of Δ(8)-tetrahydrocannabinol.

24. The process of claim 1 , wherein relative to the cannabis in step (a), the second extract includes a lower concentration of Δ(8)-tetrahydrocannabinolic acid.

25. The process of claim 1 , wherein relative to the cannabis in step (a), the second extract includes a higher concentration of Δ(8)-tetrahydrocannabinol and Δ(9)-tetrahydrocannabinol.

26. The process of claim 1 , wherein first extract comprises less than 10 wt. % in the aggregate of Δ(8)-tetrahydrocannabinol and Δ(9)-tetrahydrocannabinol.

Assignments (2)
SECURITY INTEREST Recorded Oct 18, 2024
From: AVENIR WELLNESS SOLUTIONS, INC.
To: SINDERBRAND LAW GROUP, PC
Reel/Frame 068937/0949 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 17, 2023
From: AVENIR WELLNESS SOLUTIONS, INC. F/K/A CURE PHARMACEUTICAL HOLDING CORPORATION
To: AVENIR WELLNESS SOLUTIONS, INC.
Reel/Frame 063663/0831 →
Continuity (7)
Continuation 16856609 · Apr 23, 2020
Continuation 16809958 · Mar 5, 2020
Continuation 16151436 · Oct 4, 2018
Continuation 15988484 · May 24, 2018
Continuation 14694303 · Apr 23, 2015
Continuation 14255296 · Apr 17, 2014
Related Publication 20220265744A1 · Aug 25, 2022